ARNA Financial Facts

Gain from valuation of derivative liabilities: 1.01M
Research and development: 27.03M
See Full Income Statement

Current portion of lease financing obligations: 2.27M
Total current liabilities: 61.3M
See Full Balance Sheet

Arena Pharmaceuticals, Inc. (ARNA) Earnings

  |   Expand Research on ARNA
Next EPS Date 11/7/14 *Est. EPS Growth Rate -83.3% *Last Qtr.
Average EPS % Beat Rate +35.2% Revenue Growth Rate -81.4% *Last Qtr.
Average % Move 1-Wk after EPS +3.3% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/9/10 Q310 -$0.31-$0.23 -$0.08N/AN/A N/A Details
3/11/11 Q410 -$0.23-$0.21 -$0.02$4.01M$4.81M N/A Details
5/10/11 Q111 -$0.35-$0.21 -$0.14$3.92M$3.29M N/A Details
8/9/11 Q211 -$0.16-$0.16 $0.00$3.26M$3.35M N/A Details
3/14/12 Q411 -$0.16-$0.15 -$0.01$2.08M$3.49M N/A Details
11/9/11 Q311 -$0.16-$0.14 -$0.02$3.46M$3.37M N/A Details
11/7/13 Q313 -$0.08-$0.12 +$0.04$3.6M$5.3M N/A Details
8/1/14 Q214 $0.03-$0.11 +$0.14$12.8M$9.81M N/A Details